Definiens Digital Pathology Software Utilized for Hamner Institutes Liver Toxicology Study
News Jun 07, 2010
Definiens, the number one Enterprise Image Intelligence® company, has announced that The Hamner Institutes for Health Sciences is utilizing Definiens image analysis software in a comprehensive liver toxicology study.
The Hamner Institutes will utilize Definiens TissueStudio™ and Definiens Developer XD to develop an application that automatically analyzes images of liver tissue slides. The application will identify and quantify apoptotic nuclei in hundreds of whole-slide liver tissue section images, expediting the image analysis process.
“The use of automated image acquisition and analysis technologies greatly expands our ability to identify and quantify low-frequency adverse events resulting from chemical exposure,” said Dr. Russell Thomas, Senior Investigator and Director of Genomic Biology and Bioinformatics at The Hamner Institutes. “We are using Definiens digital pathology software to measure small changes in the background rate of apoptosis. This capability allows us to assess the effects of chemicals at environmentally-relevant doses. Initial studies demonstrated that Definiens’ software delivers highly accurate and reproducible analysis results.”
Staining liver tissues with terminal transferase and biotin-16-dUTP antibodies (TUNEL Fluorescent Staining), researchers at The Hamner Institutes aim to measure changes in the background rate of apoptosis following chemical treatment. The goal of the study, which includes 1680 slide sections from 168 animals and is projected to conclude in the spring of 2011, is to better understand whether changes in the background rate of apoptosis contribute to the tumor-promoting effects of the chemicals studied.
The Hamner Institutes is an independent, nonprofit research and development organization that strives to improve public health through better predictive assessments of chemical and drug safety. Since its founding in 1974, it has developed models and applications to assess the impact of environmental exposures, including toxins, on human health. The Hamner Institutes applies the latest technologies to understand the effects of chemicals and drugs on human health.
The addition of Definiens TissueStudio™ and Definiens Developer XD provides The Hamner Institutes with the ability to analyze large numbers of histological and cell-based images to study these chemical effects. Definiens image analysis software was chosen for the study because it provides the flexibility to generate and modify algorithm rule-sets to identify and measure rare occurrences, such as apoptosis in liver tissue sections.
After successfully measuring the background rates of apoptosis in the control animals, the researchers at The Hamner Institutes plan to conduct a pilot study to statistically detect changes in the background apoptosis rate following chemical treatment and, eventually, measure the change in background rates of apoptosis in a full-time course and dose-response study.
“Definiens’ digital pathology software is uniquely suited to the complex challenges of this liver toxicology study,” said Thomas Colarusso, General Manager and Vice President Sales North.
America for Definiens Life Sciences division. “Our context-based image analysis technology will enable The Hamner Institutes to automate, identify and quantify biomarkers quickly and efficiently.”
Novel Chemistry Technique Simplifies Late-Stage Modification of Drug CompoundsNews
Chemists at The Scripps Research Institute (TSRI) have invented a technique that overcomes a long-standing problem in organic chemistry and should streamline the process of discovery and development for many new drugs.READ MORE
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE